
BehaVR and Fern Health Merge To Form RealizedCare, Launch Digital Care Management Platform to Unlock the Value of Digital Therapeutics
17.11.2023 08:51:52 CET | Grünenthal Group | Press release
The merger will accelerate a new digitally-powered care management solution for chronic pain and beyond; Pharmaceutical company Grünenthal becomes the largest investor in the combined enterprise
NASHVILLE, Tenn., Aachen, Germany, NOVEMBER 16, 2023 – BehaVR, a pioneering force in digital therapeutics (DTx) experiences, and Fern Health, a virtual chronic pain management program, today announced the signing of an agreement to merge their businesses and create a new digital care management solution for chronic pain. The new offering will be branded as RealizedCare, and strives to meet the increased demand for evidence-based, more scalable, impactful and economically viable solutions for a range of mental and behavioral health burdens, beginning with chronic pain.
RealizedCare introduces an advanced care management platform powered by DTx technology. The platform’s approach, which combines DTx with traditional wraparound services, will unlock value-based chronic pain management at scale. Grünenthal, a global research-based pharmaceutical company and parent company of Fern Health, has partnered with RealizedCare as a strategic investor, delivering on its shared vision of a world free of pain.
Chronic pain impacts an estimated 52 million adults in the United States and drives an estimated $261 billion to $300 billion in direct healthcare costs per year. Due to the highly individual and complex nature of persistent pain, health plans and providers have long struggled to adequately support those who experience it and manage the associated costs. RealizedCare’s disruptive offering represents a pivotal moment in the evolution of care delivery.
“We’ve spent the last five years building, perfecting and validating evidence-based, immersive, digital therapeutics designed to address fear and pain,” said Aaron Gani, founder and CEO of BehaVR and CEO of RealizedCare.“Through this new offering, we will unlock the power of those interventions to scale personalized care to individuals impacted by chronic pain in a way that prioritizes outcomes, and offers the integrated support needed to manage these symptoms effectively.”
RealizedCare will work with health plans, employers and value-based providers to identify, assess and engage members with chronic pain via a fully managed solution. With RealizedCare, members and patients are guided through a personalized care journey, receive digital interventions, are connected to a community with lived experience of chronic pain and can be referred directly to clinicians when necessary.
“Chronic pain is on the rise globally and the demand for holistic, multi-modal care via digital solutions is growing. By positioning Fern Health at this nexus, we have developed truly innovative solutions for those who suffer from chronic pain and partnered with leading health services in the US. Through this merger, we will be able to extend the reach and impact of multi-modal digital health solutions to more people living with chronic pain,” said Gabriel Baertschi, CEO, Grünenthal.
Fern Health’s chronic pain programs were initially developed in collaboration with pain
management clinicians at Massachusetts General Hospital. Fern Health has also partnered with
major US healthcare services like the MetroHealth System and WebMD Health Services to bring its innovative virtual offering delivering education, activities, and tools to help people address the physical, emotional, and social causes of pain, to individuals and employers. The combination of Fern Health's innovative virtual offering with BehaVR's expertise in building immersive, evidence-based DTx will enhance engagement and impact across RealizedCare's suite of clinically validated therapeutics. This suite includes treatments across the spectrum of mental and behavioral conditions, including treatments for serious mental illness.
In multiple randomized controlled trials, including real world outcomes from over 23,000 encounters, patients who previously experienced BehaVR’s PNE (Pain Neuroscience Education) VR program had 2 ½ times greater likelihood of a clinically significant reduction in disability, as well as 20 percent improvements in pain catastrophizing.
As part of the new offering, members will be assigned a pain coach and receive a personalized care plan, inclusive of pain neuroscience education, mindfulness practices, calming experiences, and immersive, gamified, graded exercise and movement. Members will also have access to PatientsLikeMe's supportive community of over 160,000 people living with chronic pain who will provide peer and community support from those that understand the complexities and challenges of living with chronic pain. PatientsLikeMe is a trusted digital health community that supports health consumer acquisition, engagement and activation, and is the first collaborator to support the member engagement aspect of this new offering.
“We are thrilled to join RealizedCare and to enable this new offering, which supercharges the scalability and economic viability of traditional care management programs,” said Brad Lawson, CEO, Fern Health. “This is a completely different care experience for chronic pain patients that should mean better managed pain, fewer analgesic injections, fewer trips to the ER, fewer unnecessary surgeries, and ultimately, an improved quality of life.”
Contacts
Fabia Kehren
Head of External Communication Grünenthal
E-Mail: Fabia.Kehren@grunenthal.com
About Grünenthal
Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the US. Our products are available in more than 100 countries. In 2022, Grünenthal employed around 4,400 people and achieved sales of € 1.7 bn.
More information: www.grunenthal.com
About Fern Health
Available through employers and health plans, Fern Health's virtual pain platform addresses the underlying causes of persistent pain, not just the symptoms. Guided programs deliver exercise therapy, interventions for sleep, nutrition, daily movement, and emotional health. Every member is supported through pain-focused 1:1 clinical coaching and pain neuroscience education to improve function, reduce pain, and avoid unnecessary healthcare costs. Fern Health is majority owned by German life science company Grünenthal International, with other minority investors. More information: www.fernhealth.com
Subscribe to releases from Grünenthal Group
Subscribe to all the latest releases from Grünenthal Group by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Grünenthal Group
Grünenthal licenses exclusive South Korean rights to Qutenza® to BCWorld Pharm5.3.2026 08:55:52 CET | Press release
Aachen, Germany & Yeoju, South Korea, 5 March 2026 – Grünenthal, a global leader in pain management and related diseases, and BCWorld Pharm Co., Ltd. ("BCWP"), a specialty company actively expanding and diversifying its pain management portfolio through global open innovation partnerships, announced today that they have entered into a definitive agreement whereby BCWP will have the exclusive South Korean rights to Qutenza®, a topical, non-systemic, non-opioid patch treatment. In Europe, the product is indicated for the management of peripheral neuropathic pain.
Grünenthal takes full ownership of Grünenthal Meds, the joint venture established with Kyowa Kirin for its established medicines brands2.3.2026 10:30:11 CET | Press release
Grünenthal acquired Kyowa Kirin International’s 49% stake in ‘Grünenthal Meds’, a joint venture formed in 2023 to market the established medicines portfolio from Kyowa Kirin International. Through this acquisition, Grünenthal assumes the sole responsibility of a portfolio comprising 12 brands across six therapeutic areas and >60 markets.
Grünenthal licenses exclusive Australian rights to Qutenza® to Clinect24.2.2026 09:15:09 CET | Press release
Aachen, Germany & Victoria, Australia, 24 February 2026 – Grünenthal, a global leader in pain management and related diseases, and Clinect Pty Ltd ("Clinect"), an Australian based company focussed on supporting access to unique products, announced today that they have entered into a definitive agreement whereby Clinect will have the exclusive Australian rights to Qutenza®, a topical, non-systemic, non-opioid patch indicated for the management of peripheral neuropathic pain. Under the agreement, Clinect will be responsible for obtaining marketing authorisation for Qutenza® in Australia and, upon approval, marketing and distributing the product in Australia. "We firmly believe in the benefits that this non-opioid treatment option can provide to people suffering from peripheral neuropathic pain and continue to work on expanding its footprint to reach more patients worldwide," says Jan Adams, Chief Commercial Officer (CCO) at Grünenthal. "Clinect is an experienced specialist with a strong
Grünenthal’s proprietary NaV 1.8 inhibitor enters clinical development18.2.2026 11:22:04 CET | Press release
Aachen, Germany, 18 February 2026 – Grünenthal announced today that the first healthy volunteers have been enrolled in a Phase I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor. The orally administered investigational medicine aims to provide a non-opioid therapy option across a range of acute and chronic pain conditions. Full results of the trial are expected in the second half of 2026.
Grünenthal licenses exclusive Canadian rights to testosterone replacement therapy Nebido® to Apotex5.2.2026 16:02:38 CET | Press release
Aachen, Germany & Toronto, Canada, February 5, 2026 – Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, today announced they have entered into a licensing agreement whereby Apotex will have the exclusive Canadian rights to Nebido® (testosterone undecanoate), a long-acting injectable therapy indicated for the treatment of male hypogonadism (testosterone deficiency).[1]